Fate Therapeutics (FATE) Cash from Operations (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Cash from Operations came in at 30822000.0 in Q1 2026, up 8.83% YoY from 28319953.2 in Q1 2025, and down 32.2% on a QoQ basis from 23314000.0 in Q4 2025.
Powered by 
Analysis
Fate Therapeutics (FATE) Cash from Operations (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Cash from Operations data on file, last reported at 30822000.0 in Q1 2026.
- Quarterly Cash from Operations rose 8.83% year-over-year to 30822000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 103097000.0 (up 16.41% YoY) and the FY2025 annual result came in at 106084000.0, up 13.66% from the prior year.
- Cash from Operations fell to 30822000.0 in Q1 2026, from 23314000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 23314000.0 in Q4 2025 to a low of 75389000.0 in Q4 2022.
- A 5-year average of 37661823.53 and a median of 32306000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 138.46% — and 2023, when it soared 55.33%.
- Tracing FATE's Cash from Operations over 5 years: stood at 75389000.0 in 2022, then soared by 51.4% to 36637000.0 in 2023, then grew by 24.12% to 27799000.0 in 2024, then climbed by 16.13% to 23314000.0 in 2025, then tumbled by 32.2% to 30822000.0 in 2026.
- The last three Cash from Operations figures came in at 30822000.0 (Q1 2026), 23314000.0 (Q4 2025), and 24374000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - | -23.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.40 Mn |
| Mar 31, 2026 | -30.82 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -24.37 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Mar 31, 2025 | -33.81 Mn |
| Dec 31, 2024 | -27.80 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -32.31 Mn |
| Mar 31, 2024 | -33.35 Mn |
| Dec 31, 2023 | -36.64 Mn |
| Sep 30, 2023 | -38.27 Mn |
| Jun 30, 2023 | -28.49 Mn |
| Mar 31, 2023 | -28.86 Mn |
| Dec 31, 2022 | -75.39 Mn |
| Sep 30, 2022 | -55.05 Mn |
| Jun 30, 2022 | -53.16 Mn |
| Mar 31, 2022 | -64.61 Mn |
| Dec 31, 2021 | -70.29 Mn |
| Sep 30, 2021 | -33.38 Mn |